News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
Eli Lilly (LLY) Release: Jardiance (Empagliflozin) To Be Studied For The Treatment Of People With Chronic Heart Failure 4/19/2016
Bristol-Myers Squibb (BMY) Release: First Presentation Of Overall Survival Data For Opdivo (Nivolumab) Shows Significant Survival Benefit At One-Year Versus Investigator’s Choice In Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck 4/19/2016
Immune Pharma Release: New Biomarker Data To Be Presented At AACR Helps Predict Overall Survival In Patients With Acute Myeloid Leukemia (AML) Treated With Ceplene And Low-Dose IL-2 Immunotherapy, Including Those Over 60 Years Of Age 4/19/2016
Janssen Release: New Data From U.S. Post-Approval Study Assess Ischemic Stroke And Intracranial Hemorrhage Rates In People With Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban With Warfarin And Apixaban With Warfarin 4/18/2016
New Data Suggesting Positive Effects Of Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) On Brain Volume Loss And Retinal Nerve Fibers To Be Presented At American Academy of Neurology 4/18/2016
Janssen Release: Real-World Study Further Confirms Safety Profile Of XARELTO In Nearly 45,000 People With Non-Valvular Atrial Fibrillation (NVAF), Including Those With Concomitant Diabetes 4/4/2016
Novo Nordisk A/S (NVO) Release: Victoza (liraglutide [rDNA origin] injection) Provided Superior Hba1c Reductions In Adults With Type 2 Diabetes Compared To Continued Sitagliptin Treatment 4/4/2016
Health Canada Approves BioPharmX Study Of Violet Iodine 4/4/2016
Cardiome Pharma Corp. (COM.TO) Announces Publication Of Independent Study Comparing BRINAVESS To Ibutilide In Patients With Recent-Onset Atrial Fibrillation 3/31/2016
Specialised Therapeutics Asia Release: Novel Multiple Myeloma Drug Aplidin Shows Positive Results In Pivotal Phase 3 Study 3/31/2016
AstraZeneca PLC (AZN) Release: BRILINTA Preferred Over Clopidogrel In Updated American College of Cardiology And AHA Guideline In Acute Coronary Syndrome 3/31/2016
Janssen Research & Development Release: First Phase 3 Trial Of Daratumumab In Combination With Standard Therapy In Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint In Planned Interim Analysis 3/30/2016
Boehringer Ingelheim Launches RE-COVERY DVT/PE: Global Observational Study On Management Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) With Pradaxa (Dabigatran Etexilate) 3/23/2016
AstraZeneca PLC (AZN)'s Brilinta Fails to Hit Main Goal of Stroke Study 3/23/2016
BioPharmX Initiates Post-Market Phase IV Study For Fibrocystic Breast Condition (FBC) And Cyclic Mastalgia 3/22/2016
SoCal's Aerie (AERI) Reports Positive Safety Data for Rhopressa 3/18/2016
Gilead (GILD) Shuts Down Six Zydelig Trials Following European Medicines Agency Review 3/17/2016
Viralytics Ltd (VLA.AX) Release: Positive CAVATAK Clinical Data Presented At 2016 European Association Of Urology Congress 3/15/2016
Janssen Pharmaceuticals, Inc. Release: First Real-World Evidence Comparing An SGLT2 Inhibitor With DPP-4 Inhibitors Shows Adults With Type 2 Diabetes Achieve Greater Blood Glucose Control With INVOKANA (canagliflozin) 3/14/2016
Boehringer Ingelheim Release: New Analyses: Adding SPIRIVA RESPIMAT Effective For Uncontrolled Asthma - Regardless Of Allergy Subtype 3/8/2016
New Novartis AG (NVS) Data Show Cosentyx Demonstrated Sustained Superiority In Skin Clearance (PASI 90) Versus Stelara At Week 52 3/7/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Long-Term Safety Data Presented At American Academy of Dermatology Congress 3/7/2016
AstraZeneca PLC (AZN), Novo Nordisk A/S (NVO) Investors Pin Hopes on Data from Two Closely-Watched Trials 3/2/2016
AEterna Zentaris (AEZS) Reports On Zoptrex Development Progress In China 3/1/2016
Arizona Pharmaceuticals Release: New Analysis Re-Affirms IR-Niacin As Evidence-Based Therapy For Dyslipidemia 3/1/2016
Female Libido Drug that Valeant (VRX) Bought for $1 Billion Gets Mixed Reviews 3/1/2016
Boehringer Ingelheim Release: New Analysis Confirms OFEV® (Nintedanib) Slows Disease Progression In IPF And Reduces Risk Of Acute Exacerbations 2/25/2016
ChromaDex, Inc. Announces Commencement Of An Obesity-Related Clinical Study Of NIAGEN In Collaboration With The University of Copenhagen And Aarhus University 2/22/2016
Amgen (AMGN)'s Aranesp Meets Primary Goal in Late Stage Trial 2/16/2016
Cumberland Pharmaceuticals (CPIX) Release: Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics 2/10/2016
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range Of Measures 2/9/2016
EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase III Clinical Study For BOW015 (Infliximab Biosimilar) 2/9/2016
Valeant (VRX) Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a Placebo 2/3/2016
Journal of Clinical Oncology Publishes Results From The STRIVE Trial Of enzalutamide Compared To bicalutamide In Castration-Resistant Prostate Cancer 1/27/2016
First U.S. Patient Treated Following FDA Approval Of Cook Medical’s Zenith Alpha Thoracic Endovascular Graft 1/26/2016
Omeros Corporation (OMER) Release: Disclosure Of Omidria Post-Launch Study Findings To Occur At Hawaiian Eye And Retina Conference 1/18/2016
Hi-Tech Pharmaceuticals Announces OTC Nationwide Launch Of New Diet Pill -- Ionamin -- Backed By Clinical Study 1/12/2016
Regeneron (REGN) Investors Get Jitters From False Praluent Data 1/8/2016
ImaginAb, Inc.'s PSMA Imaging Agent Detects More Lesions Compared To Standard Imaging Methods For Detection Of Prostate Cancer In Phase I/Ila Study 1/6/2016
Teva (TEVA), Active Biotech (BTPC) Stop Higher Doses of Laquinimod in Two Multiple Sclerosis Trials 1/4/2016
Primary Endpoint Met in Baxalta (BXLT) and Momenta (MNTA)'s Biosimilar Study of Humira 12/22/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-166 (Ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis 12/16/2015
Collegium (COLL) Announces Publication Of Nasal Human Abuse Potential Study In American Academy Of Pain Medicine 12/16/2015
Zydelig Study May Finally Transform Gilead (GILD) into a Cancer Powerhouse 12/11/2015
Defective Device Forces Regulators to Take a Hard Look at Bayer (BAY)'s Xarelto Trial 12/9/2015
Merck & Co. (MRK) Release: Findings Across A Range Of Hematological Cancers Add To The Growing Breadth Of KEYTRUDA (Pembrolizumab) Data 12/8/2015
Janssen Pharmaceutical Release: Real-World Data Confirms Safety And Efficacy Profile Of XARELTO, With Shorter Hospital Stays, For The Treatment Of Deep Vein Thrombosis 12/8/2015
ContraVir Reports Key CMX157 Data At HEP DART 2015 Demonstrating Enhanced In Vitro Safety Profile Compared To Viread 12/8/2015
Merck & Co. (MRK) Release: Findings Across A Range Of Hematological Cancers Add To The Growing Breadth Of KEYTRUDA (Pembrolizumab) Data 12/8/2015
SteadyMed (STDY) Demonstrates Potential For Reduced Infusion Site Sensitivity Associated With Trevyent Compared To Remodulin 12/7/2015
AbbVie (ABBV) Release: IMBRUVICA (Ibrutinib) Phase 3 RAY Data Show Significant Reductions In Disease Progression Versus Temsirolimus In Relapsed/Refractory Mantle Cell Lymphoma Patients 12/7/2015
Researchers Find Additional Benefits of Novartis AG (NVS)'s Heart Failure Drug Entresto 12/3/2015
H. Lundbeck A/S (LUN.CO) Release: Largest Prospective Study Evaluating The Effect Of Vigabatrin On Vision 11/25/2015
BioMarin (BMRN) Stocks Drop After FDA Panel is Critical of DMD Treatment Drisapersen 11/23/2015
VBL Therapeutics (VBLX) Announces Significant Improvement Of 12 Month Overall Survival With VB-111 Compared To Pooled Data From Four Avastin Studies At The Annual Meeting Of The Society For Neuro-Oncology 11/19/2015
Astellas (ALPMY) Announces Results From The First Head To Head Study Comparing QUTENZATM (Capsaicin 8% Patch) With Current Standard Of Care In Patients With Peripheral Neuropathic Pain 11/19/2015
Merck & Co. (MRK) Provides Update On REVEAL Outcomes Study 11/13/2015
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From A Phase IV Study To Assess And Compare The Effects Of Silenor 6 Mg And Zolpidem 10 Mg On Balance, Cognitive Performance, And Arousability 11/13/2015
AstraZeneca PLC (AZN) Release: PEGASUS-TIMI 54 Sub-Analysis Outlines Long-Term Tolerability Data For BRILINTA 11/10/2015
Boehringer Ingelheim Release: New Jardiance (Empagliflozin) Data Show Improved CV Outcomes Regardless Of Heart Failure Status At Baseline 11/9/2015
ArmaGen Technologies, Inc. Receives Rare Pediatric Disease Designation From FDA For AGT-181 For The Potential Treatment Of Hurler Syndrome (Mucopolysaccharidosis Type I) 11/5/2015
Pfizer (PFE) Release: New Data Continue To Characterize The Safety And Efficacy Of XELJANZ (Tofacitinib Citrate) In The Treatment Of Rheumatoid Arthritis 11/2/2015
FDA Bestows Merck & Co. (MRK)'s Keytruda with Breakthrough Status to Treat Advanced Colorectal Cancer 11/2/2015
Boehringer Ingelheim Release" CHEST: New Sub-Analyses Show Improvement In COPD Patient Outcomes With Spiolto Respimat 10/28/2015
Momenta (MNTA) Announces Publication Of Two Glatopa (Glatiramer Acetate Injection) Manuscripts 10/26/2015
Mundipharma AG: New Study Provides Insights Into Potential Treatment Of Severe Pain In Parkinson’s Disease With Prolonged-Release Oxycodone/Naloxone 10/20/2015
Novartis AG (NVS) Cancer Drug May Help Parkinson's Patients 10/19/2015
Sunovion Pharmaceuticals Inc. To Present Health Outcomes Data Supporting Brovana® (Arformoterol Tartrate) Inhalation Solution In Patients With COPD At The 2015 American College of Chest Physicians Annual Meeting 10/19/2015
EMD Serono Announces Publication Of PRISMS-15 Yr Follow-Up Study In Patients Using Rebif (interferon beta-1a), Focused On Factors Influencing Outcomes In RRMS 10/13/2015
Abbott (ABT)'s Absorb Passes First Large Test 10/13/2015
Indian Drugmakers Like Cipla (CIPLA) and BDR Pharma Work on Hepatitis C Cocktails Impossible in the U.S. 10/12/2015
Amgen (AMGN) Release: New Data Show Greater Bone Mineral Density Gains With Prolia (Denosumab) Compared With Zoledronic Acid 10/12/2015
Gedeon Richter (RIG2.F) Release: Full Results Of PEARL IV Study Presented At The European Society Of Gynaecological Endoscopy (ESGE) Congress Confirms The Efficacy Of Ulipristal Acetate 5 Mg For The Long Term Management Of Uterine Fibroids 10/9/2015
Sanofi Genzyme (SNY) Touts Long-Term Data for Multiple Sclerosis Drug Lemtrada 10/8/2015
Marathon Pharmaceuticals, LLC Receives Rare Pediatric Disease Designation From FDA For Deflazacort As A Potential Treatment Of Duchenne Muscular Dystrophy 10/7/2015
AstraZeneca PLC (AZN) Release: SYMBICORT Real-World Study Results Published In The International Journal Of COPD 9/30/2015
Boehringer Ingelheim Release: New Data Demonstrate Sustained Long-Term Efficacy Of OFEV* On Slowing Disease Progression And Safety In Patients With IPF 9/29/2015
Patients With Aggressive Form Of Melanoma Lived For More Than Two Years On Average When Taking Novartis Pharmaceutical Corporation (NVS) Therapies Tafinlar + Mekinist 9/28/2015
Boehringer Ingelheim Release: New Head-to-Head STIOLTO RESPIMAT Data Presented At ERS Annual Congress 9/28/2015
Alimera Sciences (ALIM) Announces ILUVIEN Study Results Presented At 15th Euretina Congress 9/24/2015
Hemispherx (HEB) Reports Article By Senior Authors From Italian Ministry Of Health And Related Agencies Suggesting Broad Applicability Of Ampligen To Multiple Sclerosis 9/23/2015
More Than 50 Presentations Of New Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured At ECTRIMS 9/23/2015
ViiV Healthcare Release: New Phase IIIb/IV Data Show Switching To Once-Daily Triumeq Maintains HIV Viral Suppression 9/23/2015
MerLion Pharmaceuticals GmbH’s Finafloxacin Shown To Be More Efficacious Than Ciprofloxacin In The Treatment Of Complicated Urinary Tract Infections 9/21/2015
ERS 2015: Landmark Year For Boehringer Ingelheim’s Respiratory Portfolio - New Data For COPD, IPF And Asthma Treatments 9/21/2015
AmpliPhi Biosciences Corporation (APHB) Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model 9/21/2015
New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company (MDCO) 9/21/2015
Eli Lilly (LLY) Diabetes Drug Slashes Deaths in Patients With Heart Risk 9/18/2015
Novo Nordisk A/S (NVO)’s Victoza Beats Sanofi (SNY)’s Lixisenatide in Head-to-Head Study, Company Says 9/17/2015
Merck & Co. (MRK)'s Once-Weekly Diabetes Drug Works Same as Januvia; Drugmaker Plans to File Drug by End of 2015 9/17/2015
Amicus (FOLD) Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA 9/15/2015
GlaxoSmithKline (GSK), Theravance (THRX)'s Breo Fails to Extend Lives in Ambitious Study 9/10/2015
Bristol-Myers Squibb (BMY) And Pfizer (PFE) Enroll First Patient In Phase 4 AUGUSTUS Trial To Evaluate Safety Of Eliquis (Apixaban) In Nonvalvular Atrial Fibrillation Patients With A Recent Acute Coronary Syndrome Or Undergoing Percutaneous Coronary Intervention 9/9/2015
GlaxoSmithKline (GSK) And Theravance (THRX) Announce Results From The SUMMIT COPD CV Survival Study 9/9/2015
DelMar Pharmaceuticals Presents Clinical Protocol For Advancement Of VAL-083 Into Phase IV Studies As A Treatment For Non-Small Cell Lung Cancer 9/8/2015
Collegium (COLL) To Present Highlights From Xtampza ER (Oxycodone Extended-Release Capsules) Clinical Development Program At Painweek 9/4/2015
Regeneron (REGN) And Sanofi (SNY) Announce New Positive Praluent (alirocumab) Phase 3 Data Presented At ESC Congress 2015 9/1/2015
Merck & Co. (MRK) Release: New Analyses From The IMPROVE-IT Study With VYTORIN (Ezetimibe And Simvastatin) 9/1/2015
Boehringer Ingelheim Release: New Analysis Shows Idarucizumab Enables Rapid Initiation Of Emergency Surgery In Dabigatran-Treated Patients 9/1/2015
Eli Lilly (LLY)'s Diabetes Drug Jardiance May Put the Brakes on Heart Disease 8/28/2015
Intarcia Diabetes Implant Beats Merck & Co. (MRK)'s $6 Billion Drug in Head-to-Head Study 8/20/2015
Merck & Co. (MRK) Release: New Analyses From The IMPROVE-IT Outcomes Study Of VYTORIN (Ezetimibe And Simvastatin) And The TECOS Cardiovascular Safety Trial Of JANUVIA (Sitagliptin) Will Be Presented At The European Society of Cardiology Congress 8/20/2015
Novartis AG (NVS) Reports Third Case of PML in Relapsing MS Patient Treated with Gilenya 8/19/2015
Veloxis Pharmaceuticals A/S (VELO) Envarsus XR Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis 8/17/2015
GlaxoSmithKline (GSK) Hopes Huge Trial Will Revive Flagging Lung Drug Biz 8/14/2015
Roche (RHHBY)'s Avastin Not Linked to Higher Risk of Blindness 8/14/2015
Results From First Human Clinical Study Demonstrate ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Effectively Increases The Co-Enzyme NAD+ And Is Safe 8/12/2015
Oasmia's Paclical Does Well in Head to Head Study with Celgene (CELG)'s Abraxane 8/4/2015
Pfizer (PFE) Pulls Plug on OTC Lipitor After Trial Failure 7/30/2015
Takeda (TKPYY) Announces Completion Of The Pioglitazone Post-Marketing Commitment And Submission Of Results To The European Medicines Agency, The European Medicines Agency And The PMDA 7/30/2015
AVANIR Pharmaceuticals (AVNR) Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference 7/23/2015
Portola Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not 6/25/2015
Collegium (COLL) Announces Publication of "Comparing the Effect Of Tampering On The Oral Pharmacokinetic Profiles Of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," In Pain Medicine 6/25/2015
Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence At 60 Mg Dose 6/25/2015
Protein Sciences Corporation Release: New Clinical Study of Flublok Influenza Vaccine Shows That Groundbreaking Flublok Is More Effective Than The Traditional Flu Shot 6/25/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Differentiated Pharmacokinetic Profile Compared To Twice-Daily Prograf Or Once-Daily Astagraf XL In Stable Kidney Transplant Patients 6/24/2015
MediciNova, Inc. Announces New Article Published On MN-166 (Ibudilast) In Addiction Biology 6/16/2015
Kyowa Hakko USA, Inc. Release: Combination Setria Glutathione And L-Citrulline Supplementation Proven To Increase Post-Exercise Benefits 6/15/2015
Vernalis PLC (VNLPY.PK) Announces CCP-07 Starts 12 Month Stability Testing 6/11/2015
Zealand Pharma  (ZEAL.CO) Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial 6/9/2015
Zealand Pharma  (ZEAL.CO) Informs Of Updates Given By Sanofi (SAN.PA) On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes 6/9/2015
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SAN.PA) Has Informed Of Results From Getgoal Duo-2, Showing Advantages Of Lyxumia Versus Rapid-Acting Insulin As Add-On To Lantus For The Treatment Of Type 2 Diabete 6/8/2015
New Data Show Superiority of Eli Lilly (LLY)'s Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes 6/8/2015
Sanofi (SAN.PA) Announces Study Program Evaluating Toujeo In A Real-Life Setting 6/4/2015
Matinas BioPharma's MAT9001 Meets Primary And Secondary Endpoints In First Human Trial Versus Vascepa 6/1/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015
FDA Grants Fast Track Designation For IntelliPharmaCeutics Rexista Oxycodone XR Incorporating PODRAS Technology 5/26/2015
Astellas Pharma US Release: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 5/18/2015
AbbVie (ABBV) Receives Orphan Drug Designation For HUMIRA (Adalimumab) From The FDA For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa (HS) 5/15/2015
Orexigen (OREX) Provides Statement On Termination Of The Light Study And Updates On Contrave Collaboration With Takeda Pharmaceuticals 5/13/2015
Boehringer Ingelheim Release: First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/13/2015
Orexigen (OREX) Aborts Required Study For Diet Drug Contrave 5/13/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation By The Hemispherx Biopharma (HEB) For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 5/11/2015
Heart-Stopping Morning Leads to Vertex (VRTX) Rise As FDA News Sees Positives 5/11/2015
Bristol-Myers Squibb (BMY) Release: Long-Term, 7-Year Study Of Nulojix (Belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction Of Death Or Graft Loss Over Cyclosporine Regimen In Kidney Transplant 5/6/2015
Kowa Pharmaceuticals America Release: New Meta-Analysis On Pitavastatin Demonstrates No Adverse Effect Compared With Placebo Or Other Statins On New-Onset Diabetes In Non-Diabetic Patients At Risk For Cardiovascular Disease 5/4/2015
Bayer HealthCare (BAY) Release: Five-Year Follow-Up Study Further Supports Effectiveness And Safety Of The Essure Procedure As A Non-Surgical, Non-Hormonal Option For Permanent Contraception 5/1/2015
Actavis (ACT) And Medicines360 Announce Publication Of ACCESS IUS Efficacy And Safety Study Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception 4/29/2015
Gilead (GILD) Offers Free Drugs in Georgia in Hep C Eradication Experiment 4/24/2015
Teva (TEVA) Presents Data Comparing Early Treatment With COPAXONE 40 Mg/Ml To Delayed Start Treatment At 67th American Academy of Neurology Annual Meeting In Washington, D.C. 4/23/2015
Effect Of Genzyme (GENZ)’s Multiple Sclerosis Treatment Lemtrada (Alemtuzumab) On Slowing Brain Atrophy And MRI Lesion Activity Maintained Through Four Years 4/23/2015
Momenta Pharmaceuticals, Inc. (MNTA) Presents Key Glatopa (Glatiramer Acetate Injection) Data At American Academy of Neurology Annual Meeting 4/20/2015
Biogen (BIIB) Release: TECFIDERA (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy For Newly-Diagnosed MS Patients 4/20/2015
AstraZeneca PLC (AZN)'s Diabetes Drug Onglyza May Increase Risk of Heart Failure, FDA Panel Reports 4/13/2015
Roche (RHHBY) Scientists Testing to See if Arthritis Blockbuster Will Work for Diabetes 4/10/2015
Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/25/2015
Deaths Review of Eli Lilly (LLY)'s Antipsychotic Zyprexa Relprevv "Inconclusive" 3/25/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion On Application For Orphan Designation By The European Medicines Agency Agency For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 3/24/2015
Hemispherx Biopharma (HEB) To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus 3/23/2015
Merz Aesthetics (Formerly Known as BioForm Medical, Inc.) Announces Primary Endpoint Met In Post-Market Clinical Study Of Xeomin (Incobotulinumtoxina) Vs. Botox® (Onabotulinumtoxina) For Glabellar Facial Lines 3/19/2015
Lundbeck Inc. (LUN.CO) Initiates Clinical Trial Evaluating Clobazam For Dravet Syndrome 3/17/2015
Boehringer Ingelheim Release: Many Atrial Fibrillation Patients At High Risk Of Stroke Fail To Receive Guideline-Recommended Oral Anticoagulant Treatment 3/16/2015
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015
Pfizer (PFE) Pain Med Lyrica Flunks Post Market Study in Adolescents 3/13/2015
Pfizer (PFE) Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia 3/13/2015
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Prurigo Nodularis 3/11/2015
Merck & Co. (MRK) Release: Two New Post-Hoc Analyses Of TRA 2°P TIMI 50 Study Showed ZONTIVITY (Vorapaxar) Added To Aspirin And/Or Clopidogrel Reduced Acute Limb Ischemia And Peripheral Revascularizations, Respectively, In Certain Patients With Peripheral Arterial Disease 3/5/2015
Merck & Co. (MRK) Release: New Data From IMPROVE-IT Study Of VYTORIN® (Ezetimibe/Simvastatin) And TRA 2ºp TIMI 50 Study Of ZONTIVITY® (Vorapaxar) To Be Presented At American College of Cardiology Scientific Sessions 2/25/2015
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/25/2015
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/20/2015
Celltrion Healthcare: Data Show The World’s First European Medicines Agency-Approved Biosimilar Monoclonal Antibody Remsima Could Reduce Cost Of Treating Crohn’s Disease By Up To €336 Million Over Five Years 2/20/2015
Novartis AG (NVS) May Already Have First True Anti-Aging Drug in Its Pipeline 2/19/2015
Regeneron (REGN) Release: NIH-Sponsored Comparative Effectiveness Trial In Diabetic Macular Edema Shows EYLEA (Aflibercept) Injection Demonstrated Significantly Greater Gains In Visual Acuity Than Both Bevacizumab And Ranibizumab 2/19/2015
Pfizer (PFE)'s Chantix Effective for Smokers 2/18/2015
Cumberland Pharmaceuticals (CPIX) Release: Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor® (ibuprofen) Injection 2/2/2015
New Study Vindicates Efficacy of Roche (RHHBY)'s Blockbuster Drug Tamiflu 2/2/2015
AstraZeneca PLC (AZN)'s Brilinta Boosted by Major Clinical Trial Success 1/14/2015
Ipsen (IPN.PA) To Present Further Data On Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (Lanreotide), At Gastrointestinal Cancers Symposium 1/13/2015
DBV Technologies Announces Publication In The Journal Of Allergy And Clinical Immunology Of Data Demonstrating That Epicutaneous Immunotherapy May Influence The Natural History Of Allergy 1/12/2015
Merck & Co. (MRK)'s Gardasil Not Linked To Multiple Sclerosis, JAMA Reveals 1/7/2015
Cerulean Pharma Inc. (CERU) Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models 1/6/2015
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Genentech (RHHBY) Provides Update On Phase 3 MARIANNE Study In People With Previously Untreated Advanced HER2-Positive Breast Cancer 12/19/2014
FDA Breakthrough Status For Genentech (RHHBY)'s Lucentis 12/17/2014
Pfizer (PFE)'s Top Selling Drug Doesn't Help Patients With Lower Back Pain 12/15/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
Hemispherx Biopharma (HEB) Announces Data Showing Inhibition Of Ebola By Ampligen® Enlarged By Howard University Research 12/9/2014
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014
Gilead Sciences, Inc. (GILD) Presents Follow-Up Data From Zydelig Registrational Studies In Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 12/8/2014
EXCLUSIVE: NHS Uses Ineffective IPF Therapy 12/5/2014
National Institute for Clinical Excellence (NICE) Requests More Info On Novartis AG (NVS)'s Xolair To Treat Chronic Hives 11/20/2014
Esperion Therapeutics, Inc. (ESPR) Climbs As CEO Lauds Merck & Co. (MRK)'s Zetia Data 11/19/2014
Merck & Co. (MRK)'s Vytorin Proves Effective; IMPROVE-IT Trial Achieves Primary Endpoint 11/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Longer-term Outcome Data From The Largest Prospective Trial Of Soliris® (Eculizumab) In aHUS Underscore The Effectiveness Of Ongoing Soliris Treatment 11/17/2014
Gilead Sciences, Inc. (GILD) Announces Harvoni Study Results In Chronic Hepatitis C Patients With Advanced Liver Disease And Those Who Failed Prior Treatment 11/11/2014
Confident Merck & Co. (MRK) Expects No Writedowns For Zetia, Vytorin Cholesterol Drugs 11/11/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents Positive Safety And Efficacy Data For QNASL® (Beclomethasone Dipropionate) Nasal Aerosol In Treating Children With Perennial Allergic Rhinitis 11/7/2014
FutureCeuticals Release: Human Clinical Study Indicates FruiteX-B® Calcium Fructoborate In Combination With Glucosamine And Chondroitin Provides Fast-Acting Joint And Flex Benefits 11/6/2014
AstraZeneca PLC (AZN)'s New Drug Olaparib May Also Work In Prostate Cancer 11/5/2014
Teva Pharmaceutical Industries Limited (TEVA) And Active Biotech AB (BTPC) Announce Expansion Of Laquinimod Clinical Development Program With New Trial In Primary Progressive Multiple Sclerosis And First Patient Screened In Huntington’s Disease Trial 11/4/2014
MYOS (MYOS) Announces Positive Safety Data Demonstrating Fortetropin's™ Lack Of Adverse Effect On Serum Lipids And Cholesterol Levels 11/4/2014
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia 11/3/2014
Boehringer Ingelheim GmbH Release: FDA Medicare Study In 134,000 Atrial Fibrillation Patients Confirms Positive Safety Profile And Effectiveness Of Pradaxa® In General Practice 11/3/2014
MediWound (MDWD) Initiates Post-Marketing Study With NexoBrid® To Treat Severe Burns In Pediatric Patients 11/3/2014
Pfizer (PFE)’s PRISTIQ® (Desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction In Adults With Major Depressive Disorder 10/29/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Report Results Of An Investigational Pilot Study Of Coadministration Of Lorcaserin Hcl And Phentermine Hcl 10/29/2014
Regeneron (REGN)'s EYLEA® Tops Rivals In Study 10/20/2014